Breast cancer drug, Lynparza, receives FDA approval – Outbreak News Today

Posted on

  1. Breast cancer drug, Lynparza, receives FDA approval  Outbreak News Today
  2. FDA OKs 1st drug aimed at women with inherited breast cancer
  3. FDA Approves First Drug To Treat Inherited Breast Cancer
  4. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study – The Lancet …  The Lancet
  5. FDA approves first treatment for breast cancer with a certain inherited genetic mutation
  6. Full coverage

The U.S. Food and Drug Administration today expanded the approved use of Lynparza olaparib tablets to include the treatment of patients with certain types of breast cancer that have spread metastasized and whose tumors have a specific inherited germline genetic mutation, making it the first drug in .Lynparza approved by US FDA in germline BRCA mutated metastatic breast cancer AstraZeneca and Merck Co., Inc., Kenilworth, N.J., US Merck known as MSD outside the US and Canada today announced that the US Food and Drug Administration FDA has approved Lynparza olaparib , for use .The approval also adds to the body of knowledge about the clinical use and value of companion diagnostics to enable personalized medicine for people with cancer. "We congratulate AstraZeneca and Merck on obtaining FDA approval of Lynparza for patients with metastatic breast cancer, which is the first .Myriad Receives FDA Approval of BRAC.ysis CDx as Companion Diagnostic for Lynparza olaparib In Patients with Metastatic Breast Cancer and personalized medicine, today announced that the U.S. Food and Drug Administration FDA approved BRAC.ysis CDx for use as a companion .

Leave a Reply

Your email address will not be published. Required fields are marked *